Treatment research in bipolar disorder: Issues and recommendations

CNS Drugs

Volumn 16, Issue 11, 2002, Pages 721-729

  Baldessarini, Ross J ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CHLORPROMAZINE; CLONAZEPAM; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; VALPROATE SEMISODIUM;

ACCIDENT; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BODY WEIGHT DISORDER; COMORBIDITY; CONFUSION; COST EFFECTIVENESS ANALYSIS; CYCLOTHYMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATALITY; HUMAN; HYPOMANIA; KIDNEY DYSFUNCTION; MORTALITY; NEUROTOXICITY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SYMPTOMATOLOGY; THYROID DISEASE;

EID: 0036034194     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216110-00001     Document Type: Review

References (52)

1. Goodwin FK, Jamison KR. Manic Depressive Illness. New York: Oxford University Press, 1990
2. Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disord 2000; 2: 3-7
3. Tohen M, Angst J. Epidemiology of bipolar disorder. In: Tsuang MT, Tohen M, editors. Textbook in Psychiatric Epidemiology. 2nd Ed. New York: John Wiley & Sons, 1995
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington, DC: American Psychiatric Association, 2000
5. Akiskal HS, Bourgeois ML, Angst J, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000; 59: S5-30
6. Baldessarini RJ, Tondo L, Hennen J. Reduced suicide risk during long-term treatment with lithium. Ann N Y Acad Sci 2001; 932: 24-43
7. Tondo L, Hennen J, Baldessarini RJ. Reduced suicide risk with long-term lithium treatment in major affective illness: A metaanalysis. Acta Psychiatr Scand 2001; 104: 163-72
8. Tondo L, Baldessarini RJ, Floris G. Long-term effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry 2001; 178 Suppl. 40: S184-90
9. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th Ed. New York: McGraw-Hill Press, 2001: 485-520
10. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: Antidepressant and antianxiety agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 10th Ed. New York: McGraw-Hill Press, 2001: 447-83
11. Brambilla P, Barale F, Soares JC. Perspectives on the use of anticonvulsants in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2001; 4: 421-46
12. Strakowski SM, Del Bello MP, Adler CM. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs 2001; 15: 701-18
13. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001; 62: 565-9
14. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebocontrolled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-12
15. Baldessarini RJ, Tondo L, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord 2000; 61: 13-22
16. Baldessarini RJ, Tondo L, Hennen J. Latency and episodes before treatment: Effects on pretreatment morbidity but not response to maintenance treatment in bipolar I and II disorders. Bipolar Disord 2002. In press
17. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatments. Pharmakopsychiatr Neuropsychopharmakol 1980; 13: 156-67
18. Kupfer DJ, Carpenter LL, Frank E. Possible role of antidepressants in precipitating mania and hypomania in recurrent depression. Am J Psychiatry 1988; 145: 804-8
19. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: A controlled comparison with spontaneous mania. Am J Psychiatry 1994; 151: 1642-5
20. Baldessarini RJ, Tondo L, Hennen J, et al. Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10: 59-75
21. Kruger S, Braunig P, Cooke RG. Comorbidity of obsessivecompulsive disorder in recovered inpatients with bipolar disorder. Bipolar Disord 2000; 2: 71-4
22. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001; 3: 181-8
23. MacKinnon DF, Zandi PP, Cooper J, et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002; 15: 30-5
24. Ghaemi SN, Pope Jr HG. Lack of insight in psychotic and affective disorders: A review of empirical studies. Harv Rev Psychiatry 1994; 2: 22-33
25. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-50
26. Bowden CL, Brugger A, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-24
27. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania: The Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702-9
28. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study: The Olanzapine HGGW Study Group. Arch Gen Psychiatry 2000; 57: 841-9
29. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-52
30. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984; 41: 1096-104
31. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled, 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: The Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-9
32. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry 2000; 57: 490-2
33. Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120-5
34. Keller MB, Lavori PW, Klerman G, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986; 43: 458-66
35. Harman JS, Mulsant BH, Kelleher KJ, et al. Narrowing the gap in treatment of depression. Int J Psychiatry Med 2001; 31: 239-53
36. Bowden CL, Swann AC, Calabrese JR, et al. Maintenance clinical trials in bipolar disorder: Design implications of the divalproexlithium-placebo study. Psychopharmacol Bull 1997; 33: 693-9
37. Gelenberg AJ, Frank E, Keller MB, et al. Evaluating pharmacologic treatments for bipolar disorder. In: Prien RF, Robison DS, editors. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York: Raven Press, 1994: 327-44
38. Prien RF, Robison DS, editors. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. New York: Raven Press, 1994: 728
39. Prien RF, Rush AJ. National Institute of Mental Health workshop report on the treatment of bipolar disorder. Biol Psychiatry 1996; 40: 215-20
40. Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. J Clin Psychiatry 1999; 60 Suppl. 5: 5-13
41. Lavori PW. Placebo control groups in randomized treatment trials: A statistician's perspective. Biol Psychiatry 2000; 47: 717-23
42. Post RM, Denicoff KD, Leverich GS. Special issues in trial design and use of placebo in bipolar illness. Biol Psychiatry 2000; 47: 727-32
43. Rush AJ, Post RM, Nolen WA, et al. Methodological issues in development new acute treatment for patients with bipolar illness. Biol Psychiatry 2000; 46: 615-24
44. Calabrese JR, Rapport DJ, Shelton MD, et al. Evolving methodologies in bipolar disorder maintenance research. Br J Psychiatry 2001; 178 Suppl. 41: s157-63
45. Geddes J, Goodwin G. Bipolar disorder: Clinical uncertainty, evidence-based medicine and large-scale randomized trials. Br J Psychiatry 2001; 178 Suppl. 4: s191-4
46. Post RM, Keck Jr PE, Rush AJ. New designs for studies of the prophylaxis of bipolar disorder. J Clin Psychopharmacol 2002; 22: 1-3
47. Baldessarini RJ, Tondo L, Viguera AC. Effects of discontinuing lithium maintenance treatment. Bipolar Disord 1999; 1: 17-24
48. Hennen J. Methods of design and analysis of experimental treatment trials in bipolar disorder. Bipolar Disord. In press
49. Coppen A, Montgomery SA, Gupta RK, et al. A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry 1976; 128: 479-85
50. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: State of the evidence. Harv Rev Psychiatry 2000; 8: 126-40
51. Klein DF. Improvement of phase III psychotropic drug trials by intensive phase II work. Neuropsychopharmacology 1991; 4: 251-8
52. Centorrino F, Hernán MA, Drago-Ferrante G, et al. Noncompliance with psychiatric outpatient visits: Associated factors. Psychiatr Serv 2001; 52: 378-80